Medscape is available in 5 Language Editions – Choose your Edition here.


Arsine Poisoning

  • Author: Kermit D Huebner, MD, FACEP; Chief Editor: Robert G Darling, MD, FACEP  more...
Updated: Apr 22, 2015


Arsine, the most toxic form of arsenic, has some properties that may make it useful as a chemical warfare (CW) agent; it is a colorless, odorless, nonirritating gas that is 2.5 times denser than air. At concentrations above 0.5 ppm, a garliclike odor may be noted; however, arsine is toxic at much lower concentrations. Arsine is often produced from the reduction of inorganic arsenic salts with the use of acids and metal cofactors such as zinc. Once in the body arsenic is readily distributed where peak serum levels occurs in approximately 60 minutes. The majority of arsenic is excreted by the kidneys, with some excretion in sweat, feces, and bile in small amounts.[1]

Although it has been investigated as a CW agent, no battlefield use has been documented. During and prior to World War II, the British studied this agent and rejected its use in the field. They concluded that arsine was more than 10 times less toxic than phosgene (CG) and was both difficult to manufacture and highly flammable. Although arsine was determined not to be useful as a battlefield CW agent, concern exists that it may be useful as a small-scale weapon of assassination or terror.

In contrast, several arsine-derived organoarsenic compounds have been developed and used as CW agents, including lewisite (beta-chlorovinyldichloroarsine), adamsite (diphenylaminearsine), Clark I (diphenylchlorarsine), and Clark II (diphenylcyanoarsine).

Possible sources of occupational exposure are many, including microchip production in the semiconductor industry and other industries in which workers are involved in galvanizing, soldering, etching, and lead plating. It may also be produced inadvertently by mixing arsenic-containing insecticides and acids.



Inhaled arsine gas is distributed rapidly and causes massive red blood cell hemolysis that can potentially lead to global cellular hypoxia. The exact mechanisms leading to hemolysis have not been fully elucidated, but oxidative cell lysis has been suggested.

A study of mice exposed to moderate-to-high levels of arsine for 90 days revealed a significant decrease in hemoglobin and hematocrit along with an increase in mean corpuscular hemoglobins and mean corpuscular hemoglobin concentrations after 5 days of exposure.[2] Blood collected at 15 and 90 days showed a less severe anemia but a greater increase in mean corpuscular volumes and absolute reticulocyte count indicating a regenerative response. At 90 days, the concentration of methemoglobin was increased along with an increase in intracellular denatured proteins, or Heinz bodies. In addition, this particular study determined that arsine gas significantly depletes reduced intracellular glutathione resulting in greater oxidative damage to red blood cells.

Other mechanisms of hemolysis may include the inhibition of catalase and the formation of reactive oxidative species (ROS), such as hydrogen peroxide, within the cell. The damage induced by free radicals causes the denaturing of hemoglobin. This ultimately is believed to promote an abnormal association of hemoglobin with the erythrocyte membrane proteins that increase fragility of the erythrocyte membrane. Many researchers believe that hemolysis is a direct result of an arsenic dihydride intermediate and elemental arsenic produced from oxidized arsine. While there is disagreement of the reactive species involved and the mechanism of destruction, it is plausible that arsine causes cellular destruction by multiple mechanisms and the oxidative pathophysiology of arsine is well supported.

To further support an oxidative mechanism, human blood exposed to arsine pretreated with a sulfahydryl inhibitor N-ethylmaleimide (NEM) in vitro, resulted in less hemolysis. These results suggest that arsine may negatively interact with membrane sulfahydrl groups resulting in ion membrane changes that ultimately lead to hemolysis.[3]

Interestingly, the oxidative cytotoxicity potential of arsenic has been used as treatment for certain malignant cancers. In treating malignant melanoma, a widely known oxidant named menadione was used in combination with arsenic to increase reactive oxidative species (ROS) production and subsequent apoptosis in tumor cells. The two were found to work synergistically with a significantly higher level of apoptosis in the group treated with arsenic.[4] Similarly patients with acute promyelocytic leukemia (APL) were treated with transretinoic acid and arsenic trioxide. Compared to control, the group treated with the combination yielded a high complete remission rate of 93% and a significantly shorter time to enter complete remission.[5]

In due course, with massive hemolysis, renal failure due to tubular destruction is an important sequelae of arsine toxicity.[6] Although arsine may have direct effects on the renal system, most of the damage is believed to result indirectly from the breakdown of red blood cells and the increased load of hemoglobin. As in rhabdomyolysis, this destroys the tubular network leading to renal failure and is further complicated by renal hypoxia secondary to the decreased oxygen capacity of the blood.




Arsine has been reported to cause immediate death at 150-250 ppm. In addition to absolute concentration, the duration of exposure is another factor that determines toxicity. Exposure to 25-50 ppm for 30 minutes or 100 ppm for less than 30 minutes may also result in massive red blood cell hemolysis and ultimately death. Symptoms may be noticed with concentrations as low as 0.15 ppm, and delirium may be seen at 10 ppm.

Most of the reported deaths are believed to have been secondary to acute renal failure. Of arsine-induced renal failure cases, 100% were fatal prior to the advent of hemodialysis. More recent mortality rates for patients with acute arsine toxicity report death in approximately 25% or less of reported cases.

Contributor Information and Disclosures

Kermit D Huebner, MD, FACEP Research Director, Carl R Darnall Army Medical Center

Kermit D Huebner, MD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, Association of Military Surgeons of the US, Society for Academic Emergency Medicine, Society of United States Air Force Flight Surgeons

Disclosure: Nothing to disclose.


Ren M Kinoshita, DO Resident Physician, Department of Emergency Medicine, Carl R Darnall Army Medical Center

Ren M Kinoshita, DO is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Osteopathic Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Robert G Darling, MD, FACEP Adjunct Clinical Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Director, Center for Disaster and Humanitarian Assistance Medicine

Robert G Darling, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Telemedicine Association, American Medical Association, Association of Military Surgeons of the US

Disclosure: Nothing to disclose.

Additional Contributors

Fred Henretig, MD Director, Section of Clinical Toxicology, Professor, Medical Director, Delaware Valley Regional Poison Control Center, Departments of Emergency Medicine and Pediatrics, University of Pennsylvania School of Medicine, Children's Hospital

Disclosure: Nothing to disclose.

  1. Lee JY, Eom M, Yang JW, Han BG, Choi SO, Kim JS. Acute kidney injury by arsine poisoning: the ultrastructural pathology of the kidney. Ren Fail. 2013. 35(2):299-301. [Medline].

  2. Blair PC, Thompson MB, Bechtold M, Wilson RE, Moorman MP, Fowler BA. Evidence for oxidative damage to red blood cells in mice induced by arsine gas. Toxicology. 1990 Jul. 63(1):25-34. [Medline].

  3. Rael LT, Ayala-Fierro F, Carter DE. The effects of sulfur, thiol, and thiol inhibitor compounds on arsine-induced toxicity in the human erythrocyte membrane. Toxicol Sci. 2000 Jun. 55(2):468-77. [Medline].

  4. Chowdhury R, Chowdhury S, Roychoudhury P, Mandal C, Chaudhuri K. Arsenic induced apoptosis in malignant melanoma cells is enhanced by menadione through ROS generation, p38 signaling and p53 activation. Apoptosis. 2009 Jan. 14(1):108-23. [Medline].

  5. Dai CW, Zhang GS, Shen JK, Zheng WL, Pei MF, Xu YX, et al. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta Haematol. 2009. 121(1):1-8. [Medline].

  6. Pullen-James S, Woods SE. Occupational arsine gas exposure. J Natl Med Assoc. 2006 Dec. 98(12):1998-2001. [Medline].

  7. Wilkinson SP, McHugh P, Horsley S, Tubbs H, Lewis M, Thould A, et al. Arsine toxicity aboard the Asiafreighter. Br Med J. 1975 Sep 6. 3(5983):559-63. [Medline].

  8. Centers for Disease Control and Prevention. Case Definition: Arsine or Stibine Poisoning. Emergency Preparedness and Response. Last updated March 4, 2005. Available at

  9. Centers for Disease Control and Prevention. Agency for Toxic Substances and Disease Registry. Medical Management Guidelines for Arsine. Last updated 9/24/07. Available at Accessed: October 5, 2007.

  10. Hesdorffer CS, Milne FJ, Terblanche J, Meyers AM. Arsine gas poisoning: the importance of exchange transfusions in severe cases. Br J Ind Med. 1986 May. 43(5):353-5. [Medline].

  11. Teitelbaum DT, Kier LC. Arsine poisoning. Report of five cases in the petroleum industry and a discussion of the indications for exchange transfusion and hemodialysis. Arch Environ Health. 1969 Jul. 19(1):133-43. [Medline].

  12. Pullen-James S, Woods SE. Occupational arsine gas exposure. J Natl Med Assoc. 2006 Dec. 98(12):1998-2001. [Medline].

  13. Danielson C, Houseworth J, Skipworth E, Smith D, McCarthy L, Nanagas K. Arsine toxicity treated with red blood cell and plasma exchanges. Transfusion. 2006 Sep. 46(9):1576-9. [Medline].

  14. Song Y, Wang D, Li H, Hao F, Ma J, Xia Y. Severe acute arsine poisoning treated by plasma exchange. Clin Toxicol (Phila). 2007 Sep. 45(6):721-7. [Medline].

  15. Kosnett MJ. The Role of Chelation in the Treatment of Arsenic and Mercury Poisoning. J Med Toxicol. 2013 Nov 1. [Medline].

  16. Anthonisen P, Nielsen B, Pedersen K, Raaschou F. 3. Clinical picture and treatment in arsine poisoning. Acta Med Scand Suppl. 1968. 496:14-22. [Medline].

  17. Caravati, Martin E. Arsenic and arsine gas. Dart RC. Medical Toxicology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. 1393-1401/chap 213.

  18. Fowler BA, Weissberg JB. Arsine poisoning. N Engl J Med. 1974 Nov 28. 291(22):1171-4. [Medline].

  19. Huq MA, Parveen F, Choudhury SR. A cheap and convenient modification of arsine generator used for arsenic estimation. Mymensingh Med J. 2003 Jan. 12(1):30-2. [Medline].

  20. Klimecki WT, Carter DE. Arsine toxicity: chemical and mechanistic implications. J Toxicol Environ Health. 1995 Dec. 46(4):399-409. [Medline].

  21. Levinsky WJ, Smalley RV, Hillyer PN, Shindler RL. Arsine hemolysis. Arch Environ Health. 1970 Mar. 20(3):436-40. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.